Diego Villa, MD, FRCPC, Discusses Bendamustine and Rituximab as Induction Therapy in MCL

Video

Diego Villa, MD, FRCPC, elaborated on the progress made with bendamustine and rituximab as induction therapy for transplant eligible and ineligible patients with mantle cell lymphoma.

Diego Villa, MD, FRCPC, of BC Cancer in Vancouver Canada, sat down to discuss induction therapy with bendamustine and rituximab (Rituxan) for transplant eligible and ineligible patients with mantle cell lymphoma (MCL) at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition, held December 7-10, in Orlando, Florida.

Transcription:

The analysis shows that you can achieve excellent response rates with an overall response rate of 88% and complete response rate of 55% when you treat all comers with BR (bendamustine and rituximab). In our study there was no difference between those over the age of 65 or under the age of 65 in terms of response rates.

Well, our studies definitely support the use of BR in the transplant ineligible population. Our studies are pretty much in line with the STiL and BRIGHT studies showing improved PFS compared to R-CHOP, and in fact our studies suggest that there might be an overall survival improvement although we included patients treated with CVPR as that was part of our previous standard.

In terms of the transplant eligible patients, our studies suggest that BR is indeed an effective induction regimen for these patients. As you know, there is no defined standard of care in the literature for the front-line therapy of mantle cell lymphoma in transplant eligible patients, and our studies certainly suggest that this could be a reasonable alternative for some patients.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.